Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Q1 2021 Oncopeptides AB Earnings Call Transcript

May 26, 2021 / 10:00AM GMT
Release Date Price: kr80.12 (-1.69%)
Operator

Hello, and welcome to the Oncopeptides Q1 Report 2021. (Operator Instructions) Today, I'm pleased to present CEO, Marty Duvall. Please go ahead with your meeting.

Martin J. Duvall;publ;CEO
Oncopeptides AB

()-

Thank you, and good morning to everyone. Marty Duvall, CEO of Oncopeptides, really pleased to be with many of you again this morning, this time to talk about our Q1 results. And I'm sure we'll have the opportunity also to touch on some of the discussions from yesterday and the top line release of the OCEAN trial.

So on Slide 2, participants joining me in today's call are Dr. Klaas Bakker, our Chief Medical Officer; and our Chief Financial Officer, Anders Martin-Löf, almost gave him a promotion there.

And on Slide 3, as a disclaimer, we're going to be making some forward-looking statements, so please look online for fairness, accuracy and balance.

And let's move then to Slide 4. So I think the key takeaways that we want you to walk away from on this update is that we are excited about the launch

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot